Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., from April 2018 until that company’s acquisition by Bristol Myers Squibb in November 2020. Prior to that, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s
Stuart Drummond has served as the Company’s Vice President and Corporate Controller since July 2021. From November 2019 until June 2021, he served as Senior Director, Corporate Controller at Sangamo Therapeutics, Inc. and from July 2016 to March 2019 he served as Corporate Controller of CareDx,
As Chief Technology Officer at Cutera, Mr. Karavitis directs research and development activities ranging from early phase R&D all the way through product development. Previous to this role, Michael served as Vice President of Research and Development of Cutera from 2012 to 2015.
